Stay Ahead of the Curve
Breaking News in Obesity Science & Innovation: Industry News & Reports
Keep pace with the latest breakthroughs in obesity science, strategic partnerships, and investment trends from BioXconomy—your trusted source for industry intelligence.
Partnerships & Collaborations
Discover how industry leaders are collaborating to advance obesity therapeutics and reshape the treatment landscape.
GSK bets $1bn on fat-targeting RNA drug that could tackle the real killer in chronic disease
Suzhou-based SiranBio has landed a deal with GSK for SA030, a siRNA that targets abdominal fat to reduce cardiometabolic risk in patients with chronic lung, liver, and kidney diseases.
An article from our editorial partner, BioXconomy.
Millie Nelson, Senior Editor, Partnering and Investment, BioXconomy
The GLP-1 ATM: How Lilly is acquiring its way out of obesity drug dependence
Eli Lilly grows through acquisitions and incretin drugs, with Q1 revenue hitting $19.8 billion, focusing on obesity, oncology, and cell therapy.
An article from our editorial partner, BioXconomy.
Nnenna Ohaka, Reporter, Partnering and Investment
AstraZeneca makes $18.5bn bet on CSPC’s weight loss drugs
AstraZeneca has entered a strategic collaboration agreement with CSPC Pharmaceuticals to strengthen its weight management drug portfolio.
An article from our editorial partner, BioXconomy.
Millie Nelson, Senior Editor, Partnering and Investment, BioXconomy
Investment & Funding
Follow the money driving obesity innovation forward. From major IPOs to venture capital rounds, track the investments fueling next-generation therapies and the companies attracting billions in backing to revolutionize weight management and metabolic health.
Kailera sets $16 IPO price, raising $625m to revolutionize obesity care
Kailera Therapeutics has announced the pricing of its IPO, and the company is set to offer 39,062,500 shares of its common stock at $16 per share.
An article from our editorial partner, BioXconomy.
Millie Nelson, Senior Editor, Partnering and Investment, BioXconomy
Ambrosia Biosciences bags $100m for obesity drugs
The $100 million oversubscribed Series B financing will be used to advance Ambrosia’s lead oral small molecule GLP-1 candidate into Phase I trials.
An article from our editorial partner, BioXconomy.
Millie Nelson, Senior Editor, Partnering and Investment, BioXconomy
Corxel advances oral GLP-1 therapy with $287m investment
Corxel Pharmaceuticals closed a $287 million Series D1 financing round to support the development of its cardiometabolic drug candidate.
An article from our editorial partner, BioXconomy.
Nnenna Ohaka, Reporter, Partnering and Investment
Innovation & Technology
See which obesity-focused companies are securing major funding and why investors are betting big on this therapeutic area. From seed rounds to public offerings, understand the financial forces shaping the industry's future.
Weight loss with a single injection? Fractyl Health is taking that bet.
Fractyl Health’s gene therapy reprograms cells to produce weight-regulating hormones, potentially replacing lifelong injections with a single treatment.
An article from our editorial partner, BioXconomy.
Nnenna Ohaka, Reporter, Partnering and Investment
Neuland announces plans for Hyderabad GLP-1 CMC facility
Located in the village of Bonthapally, the peptide CMC site is set to open summer 2026.
An article from our editorial partner, BioXconomy.
Millie Hoe, Reporter, BioProcess Insider